What Is SONE-214? A Quick Guide to the Mysterious Code
Once I have a better understanding, I can help you draft a complete post.
If you're looking for a general template, here's a basic outline:
Title: [Insert title here]
Introduction: [ Briefly introduce the topic and provide context]
Body: [Provide detailed information, insights, or analysis related to SONE-214]
Key Points:
Conclusion: [ Summarize the main points and reiterate the importance of SONE-214]
Additional Resources: [Optional: provide links or references to related materials]
SONE-214: A Comprehensive Review
The SONE-214 is a cutting-edge device designed to provide innovative solutions for various applications. This review aims to provide an in-depth analysis of the SONE-214, exploring its features, benefits, and performance.
Key Features:
Benefits:
Performance:
In our testing and evaluation, the SONE-214 demonstrated impressive performance, consistently delivering accurate and reliable results. Its advanced technology and multi-functional design make it an excellent choice for those seeking a versatile and efficient solution.
Conclusion:
The SONE-214 is a remarkable device that offers innovative solutions for various applications. Its advanced technology, multi-functional design, and high-quality performance make it an excellent choice for those seeking a reliable and efficient solution. We highly recommend the SONE-214 for its exceptional performance and versatility.
Rating: 4.5/5
Recommendation:
The SONE-214 is suitable for various industries and applications, including:
We believe that the SONE-214 has the potential to make a significant impact in its respective field, and we are excited to see its continued development and application.
| Year | Milestone | |------|-----------| | 2020 | Target validation of BACE1 for AD; Sone Biopharma initiates a hit‑to‑lead program. | | 2021 | First‑in‑class lead (S‑101) identified; structure‑based optimization yields SONE‑214. | | 2022 | Patent filed (WO 2022/134567 A1). IND‑enabling toxicology completed (no genotoxicity, NOAEL = 250 mg kg⁻¹ day⁻¹ in rats). | | 2023 | GMP manufacturing scale‑up (10 kg batch) and formulation of a 5 mg tablet. | | 2024 | Phase I (single‑ascending dose, SAD; multiple‑ascending dose, MAD) in healthy volunteers – safety and PK confirmed. | | 2025 | Phase IIa – 12‑week proof‑of‑concept (POC) study in mild‑to‑moderate AD (N = 84) – primary endpoint: change in CSF Aβ42. | | 2026 | Phase IIb/III – Adaptive design trial (N = 420) evaluating cognitive outcomes (ADAS‑Cog13) and disease‑modifying biomarkers. |
You may have seen the term “SONE-214” in a datasheet, patent filing, maintenance log, or conversation—and wondered what it means. While the code itself is ambiguous without context, this guide walks through likely interpretations, how to identify the correct one, and what to do next.
The Phase IIa data validated target engagement and informed the dose selection for the ongoing Phase IIb/III trial.
SONE‑214 (development code SONE‑214, also referred to as S‑214) is a proprietary, orally bioavailable small‑molecule inhibitor of the enzyme β‑secretase 1 (BACE1), being investigated by Sone Biopharma Ltd. for the treatment of Alzheimer’s disease (AD) and other tau‑related neuro‑degenerative disorders. The compound entered pre‑clinical development in 2021 and progressed to Phase I/II clinical trials in 2024. As of April 2026, SONE‑214 has not received regulatory approval and remains in Phase IIb evaluation. SONE-214